Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific personnel transactions rather than a financial performance report.
Material Changes
The filing discloses a specific transaction involving an increase in the notional allocation of GSK American Depositary Shares (ADSs) on August 28, 2015. This increase resulted from the revaluation of the cash element of a notional investment held within the GSK 401K plan. The transaction price was $41.25 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction notification.
Investor Verification Points
- Verify the details of the notional allocation increase for Dr. K. Slaoui (Connected Person of Dr. M. Slaoui), which involved 9 ADSs.
- Confirm the transaction date of August 28, 2015, and the price of $41.25 per ADS.
- Note that this filing does not contain quarterly or annual financial results; investors should refer to Form 20-F or other earnings releases for financial data.